| Sonoma Pharmaceuticals, Inc.: National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced | BOULDER, CO / ACCESS Newswire / November 13, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen |
| Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals to Exhibit at MEDICA 2025 in Düsseldorf | BOULDER, CO / ACCESS Newswire / November 6, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous... ► Artikel lesen |
| Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2026 Financial Results | Revenues increased 57% for the quarter and 38% for the six months ended September 30, 2025 compared to same periods last yearU.S. revenue increased 115% for the quarter and 86% for the six months ended... ► Artikel lesen |
| Jaguar Health, Inc.: Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure | SBS-IF is the second orphan disease target indication for Jaguar's intestinal failure program, which includes microvillus inclusion disease (MVID) - for which the company completed a meeting in October... ► Artikel lesen |
| Jaguar Health, Inc.: FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs | Conditional approval extended through December 2026 for the treatment of CID in dogsCID confirmatory effectiveness trial expected to conclude in February 2026, ahead of FDA's June deadline - 51 dogs... ► Artikel lesen |
| Jaguar Health, Inc.: Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders | Jaguar CEO Lisa Conte presenting December 10 from 3:25pm - 3:35pm Eastern at the Emerging Growth Conference to provide updates on near-term catalysts; Click here to registerInitial results of ongoing... ► Artikel lesen |
| Windtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech Space | Windtree is executing its corporate strategy to diversify its business with revenue and profit generating divisions CommLoan, Inc. is a tech company focused on transforming the way middle market loans... ► Artikel lesen |
| Grosvenor Invests in Wint to Strengthen Water Intelligence and Sustainability Across Global Real Estate | "Water risk and water waste are growing issues for the built environment, and Wint's technology will deliver clear value across our portfolio."BOSTON and LONDON, Dec. 3, 2025 /PRNewswire/... ► Artikel lesen |
| Windtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the Licensee | The Company has a global license agreement for the acute pulmonary that could pay up to $78.9 million in development, regulatory and commercial milestones plus low double digit royalties The licensed... ► Artikel lesen |